Home › Rhabdomyosarcoma › Ohio
Rhabdomyosarcoma clinical trials in Ohio
5 studies for Rhabdomyosarcoma are looking for participants at sites in Ohio.
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Oct 27, 2026 · NCT06441331Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
RecruitingPhase 1
12 Months – 20 Years · All sexes · Updated Oct 8, 2026 · NCT02013336A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- Children's Hospital Medical Center of Akron, Akron
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
RecruitingPhase 3
Up to age 50 · All sexes · Updated Aug 25, 2026 · NCT07466316Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
- Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT05210374A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Nationwide Children's Hospital, Columbus
RecruitingPhase 2
18 Months – 40 Years · All sexes · Updated Aug 12, 2025 · NCT05135975From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.